Cocrystal Pharma Inc Asset Resilience Ratio
Cocrystal Pharma Inc asset resilience ratio. Cocrystal Pharma Inc (COCP) has an Asset Resilience Ratio of 0.02% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Cocrystal Pharma Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cocrystal Pharma Inc (2014–2017)
Asset resilience ratio of Cocrystal Pharma Inc from 2014 to 2017. This chart shows how Cocrystal Pharma Inc's Asset Resilience Ratio has changed over time. Read Cocrystal Pharma Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cocrystal Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see COCP current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $29.00K | 0.02% |
| Total Liquid Assets | $29.00K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Cocrystal Pharma Inc maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cocrystal Pharma Inc Industry Peers by Asset Resilience Ratio
Compare Cocrystal Pharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Cocrystal Pharma Inc Asset Resilience Ratio by Year (2014–2017)
Cocrystal Pharma Inc asset resilience ratio by year from 2014 to 2017. The table below shows the annual Asset Resilience Ratio data for Cocrystal Pharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.02% | $29.00K | $121.43 Million | -0.74pp |
| 2014-12-31 | 0.76% | $1.98 Million | $259.28 Million | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more